Literature DB >> 3282893

A double-blind comparison of felodipine and hydrochlorothiazide added to metoprolol to control hypertension.

P Groom1, R J Simpson, B Singh, D E Ward, E Peers, P D Richardson.   

Abstract

Seventy-six uncomplicated hypertensive patients treated in General Practice, whose seated diastolic blood pressure (Phase V) (dBP) remained greater than or equal to 95 mmHg after a minimum of 4 weeks treatment with metoprolol 50 mg b.i.d. as antihypertensive monotherapy, were randomized to receive the selective 'calcium antagonist' felodipine 5 mg b.i.d. or hydrochlorothiazide 12.5 mg b.i.d. in addition to metoprolol 50 mg b.i.d. The trial duration was 8 weeks, the dose of the felodipine or hydrochlorothiazide being doubled after 4 weeks if 'control' of BP (dBP less than 90 mmHg) was not achieved on the initial doses. Over the trial period of 8 weeks, felodipine reduced dBP from 102 to 85 mmHg and hydrochlorothiazide from 101 to 91 mmHg; the dBP reduction in the felodipine group was greater than that in the hydrochlorothiazide group (17 vs 9 mmHg) and the attained dBP lower in the felodipine group. About half of the patients in each group required the higher dose. Both regimes were effective and well tolerated. In the dosages used, felodipine was a slightly more effective antihypertensive drug than hydrochlorothiazide when added to metoprolol. There was no apparent difference in the tolerability of the two regimes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282893     DOI: 10.1007/bf01061411

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

2.  Felodipine--a new vasodilator, in addition to beta-receptor blockade in hypertension.

Authors:  D Elmfeldt; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Haemodynamic effects of a new vasodilator drug, felodipine, in healthy subjects.

Authors:  G Johnsson; G Murray; A Tweddel; I Hutton
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.

Authors:  W Culling; M S Ruttley; D J Sheridan
Journal:  Br Heart J       Date:  1984-10

5.  Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

  5 in total
  4 in total

Review 1.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

Review 2.  Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.

Authors:  M Haria; G L Plosker; A Markham
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

3.  Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard.

Authors:  W A Littler
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

4.  Comparison of once daily felodipine 10 mg ER and hydrochlorothiazide 25 mg in the treatment of mild to moderate hypertension.

Authors:  W Koenig; M Sund; L Binner; R Hehr; J Rosenthal; V Hombach
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.